---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-003693"
form_type: "8-K"
ticker: "VNDA"
cik: "0001347178"
company_name: "Vanda Pharmaceuticals Inc."
filed_at: "2024-02-07T23:59:59+00:00"
generated_at: "2026-06-06T06:51:34.703260+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vanda reports FY2023 revenue $192.6M (-24% YoY); Q4 net loss $2.4M; PDUFA dates in 2024

## Summary
- Full year 2023 net product sales $192.6M, down 24% from $254.4M; Q4 net loss $2.4M vs income $6.9M in Q4 2022.
- HETLIOZ sales fell 47% YoY in Q4 due to generic at-risk launches; Fanapt down 7%; PONVORY added $1.6M post-acquisition Dec 7.
- Ended 2023 with $388.3M cash, down $78.6M; $100M spent on PONVORY acquisition.
- Three PDUFA target action dates in 2024: HETLIOZ insomnia March 4 (FDA cited deficiencies, Vanda sued), Fanapt bipolar April 2, tradipitant gastroparesis Sept 18.
- Vanda unable to provide 2024 financial guidance due to HETLIOZ patent litigation and generic competition.

## SEC filing metadata
- accession: 0001628280-24-003693
- form_type: 8-K
- ticker: VNDA
- cik: 0001347178
- company_name: Vanda Pharmaceuticals Inc.
- filed_at: 2024-02-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347178/000162828024003693/0001628280-24-003693-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347178/000162828024003693/vnda-20240207.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-003693
- JSON: https://secwatch.observer/filing/0001628280-24-003693.json
- Plain text: https://secwatch.observer/filing/0001628280-24-003693.txt

## Key facts
- Earnings Releases
  Vanda Pharmaceuticals Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: On February 7, 2024, Vanda Pharmaceuticals Inc. (“Vanda”) issued a press release and is holding a conference call regarding its results of operations and financial condition for the quarter and full year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1347178/000162828024003693/0001628280-24-003693-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.